Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6

Denis Delić1, Franziska Wiech2, Richard Urquhart2

  • 1Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany. denis.delic@boehringer-ingelheim.com.

Scientific Reports
|February 27, 2020
PubMed

Insights

Dipeptidyl peptidase 4 inhibitors and angiotensin II receptor blockers impact kidney disease by altering microRNA (miRNA) expression. Urinary exosomal miRNA profiling may serve as a biomarker for chronic kidney disease (CKD) progression and treatment monitoring.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Genomics

Background:

  • Dipeptidyl peptidase 4 (DPP-4) inhibitors and angiotensin II receptor blockers (ARBs) slow chronic kidney disease (CKD) progression through unclear mechanisms.
  • MicroRNAs (miRNAs) are key regulators of gene expression involved in kidney disease pathogenesis.
  • Urinary exosomal miRNAs are stable and potentially useful biomarkers for kidney conditions.

Purpose of the Study:

  • To investigate the effects of linagliptin (a DPP-4 inhibitor) and telmisartan (an ARB) on renal and urinary exosomal miRNA expression in a rat model of CKD.
  • To explore potential molecular mechanisms underlying the renoprotective effects of these drugs.

Main Methods:

  • Renal miRNA and mRNA profiling using Nanostring nCounter and RNA sequencing in sham-operated and 5/6 nephrectomized rats treated with placebo, telmisartan, or linagliptin.
  • TaqMan Array miRNA Cards were used to validate kidney miRNA changes in urinary exosomes.
  • Analysis focused on miRNAs implicated in endothelial-to-mesenchymal transition and inflammation.

Main Results:

  • 5/6 nephrectomy significantly altered the expression of 20 miRNAs in the kidney (13 increased, 7 decreased).
  • Both linagliptin and telmisartan suppressed pro-fibrotic miRNAs (e.g., miR-199a-3p) and restored anti-fibrotic miR-29c levels.
  • Changes in miR-29c expression in the kidney were mirrored in urinary exosomes.

Conclusions:

  • Linagliptin and telmisartan modulate specific miRNA profiles in the kidney, impacting fibrotic and inflammatory pathways.
  • Restorative effects on miR-29c are detectable in urinary exosomes.
  • Urinary exosomal miRNA profiling shows promise as a non-invasive biomarker for CKD progression and therapeutic response.

Related Concept Videos